MA-ALLURION-TECHNOLOGIES
6.7.2021 13:02:11 CEST | Business Wire | Press release
Allurion Technologies announced today two major milestones with the launch of the transformed Allurion Weight Loss Program and new worldwide brand for the company and its program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210706005001/en/
Allurion began commercial sales of its flagship Elipse® Gastric Balloon in 2016. Over the past five years, the company has treated over 50,000 patients across 40 countries. In that time, the company’s weight loss solution has evolved from a single device to a comprehensive program that combines medical, digital, and nutritional approaches to jumpstart weight loss and form lifelong healthy habits.
The new Allurion Program unveiled today features:
- The Allurion® Balloon, rebranded to reflect its synergistic role with other features in the program
- The Allurion® Virtual Care Suite, enabling end-to-end patient management through the Allurion Health Tracker, Connected Scale, and App
- Allurion Insights, offering providers real-time patient analytics and telehealth features
The Allurion Balloon is the world’s first and only procedureless™ medical device for weight loss that leads to 10-15% total body weight loss in approximately 16 weeks. Over 50,000 patients have been treated with the Allurion Balloon, and its re-branding not only reflects its role within the Allurion Program but also device improvements that have been made to optimize the patient and provider experience.
The Allurion Balloon works hand-in-hand with the Allurion® Virtual Care Suite. The Virtual Care Suite includes tools for the patient and the provider to have a 360-degree weight loss experience designed to deliver lifelong results. The patient receives the Allurion Health Tracker, Connected Scale, and App to track, monitor and support their progress while providing real-time data to their healthcare team. Allurion Insights seamlessly integrates this data with the provider and facilitates end-to-end patient management by providing real-time patient analytics and telehealth features.
The new branding launched today includes new messaging, identity, logos, and other design elements that have been incorporated across all products to deliver a consistent and unified experience to patients and providers around the globe.
“The launch of our transformed Allurion Program and our new branding is the culmination of an initiative we began over a year ago to reimagine the future of weight loss and evolve from a company that offers a product to one that offers a revolutionary experience that delivers lifelong results,” said Shantanu Gaur, M.D., co-founder and CEO of Allurion Technologies. “We worked closely with our patients and providers to develop an experience that meets their needs, and we look forward to seeing the positive impact it will have on patient outcomes around the world.”
About Allurion Technologies
Allurion Technologies is dedicated to ending obesity. The Allurion Program is a 360-degree weight loss experience featuring the Allurion Balloon, the world’s first and only swallowable, procedureless gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Connected Scale, Health Tracker, and App, and Allurion Insights. Learn more about Allurion online at www.allurion.com . Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005001/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
Credit Derivatives Determinations Committees Membership applications for 202627.3.2026 17:30:00 CET | Press release
DC Administration Services, Inc. (DCAS) would like to invite all interested Members of ISDA to apply for a position as a member of the Credit Derivatives Determinations Committees. There is a separate Determinations Committee for each of the relevant regions. Members of ISDA may apply for membership as either a Dealer Member of the Determinations Committees or a Non-Dealer Member of the Determinations Committees (as applicable). Parties wishing to apply for such a position should carefully review and submit either an executed Dealer Participation Letter (for a prospective Dealer Member) or an executed Non-dealer Committee Participation Letter (for a prospective Non-Dealer Member) by 5pm (New York time) on Friday, April 3, 2026. CCPs may also apply to participate as a CCP Member by submitting a Participating CCP Institution Letter. For more information on the process and to download the form of the relevant letter, please visit https://www.cdsdeterminationscommittees.org/about-dc-commit
Andersen Consulting indgår samarbejdsaftale med Solutia27.3.2026 15:22:00 CET | Pressemeddelelse
Andersen Consulting udvider sin tilstedeværelse i Spanien gennem en samarbejdsaftale med Solutia, en virksomhed med speciale i løsninger inden for arbejdsmiljø og sundhed samt rekruttering inden for life science- og sundhedssektoren. Solutia blev stiftet i 2014 og tilbyder omfattende tjenester og rådgivning med fokus på sunde arbejdsmiljøer, sygefravær, outsourcing af sundhedsydelser og uddannelse til organisationer på tværs af alle sektorer. Virksomheden leverer også rekrutterings- og executive search-løsninger med fokus på life science, tekniske fagfolk samt mellem- og topledelse samt dybdegående ekspertise inden for medicinal-, bioteknologi-, medico- og sundhedsindustrien. Ved hjælp af datadrevne og skræddersyede løsninger hjælper Solutia virksomheder med at optimere medarbejdereffektiviteten og tiltrække specialister. "Vores mål er at forbedre, hvordan organisationer tiltrækker, udvikler og leder medarbejdere i et stadig mere komplekst miljø," udtalte Cesar Castel, administrerende
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom